VRTX241108P550000
- 0.00
- 0.000.00%
Vertex Pharmaceuticals Newsroom
InspiroGene by McKesson Partners With Vertex To Expand Distribution Of CASGEVY, The First FDA-Approved CRISPR Gene-Editing Therapy For Sickle Cell Disease And Β-Thalassemia
Orsini Now Distributing CASGEVY (Exagamglogene Autotemcel), a Gene-Editing Therapy
Express News | Vertex Pharmaceuticals Inc : Citigroup Initiates Coverage With Buy Rating; Price Target $575
Citi Maintains Vertex Pharmaceuticals(VRTX.US) With Buy Rating, Raises Target Price to $575
Vertex Pharmaceuticals(VRTX.US) Officer Sells US$7.83 Million in Common Stock
$Vertex Pharmaceuticals(VRTX.US)$ Officer Kewalramani Reshma sold 15,198 shares of common stock on Nov 8, 2024 at an average price of $515 for a total value of $7.83 million.Source: Announcement
Chevron, Super Micro Computer Top List of Most Shorted Large-cap Stocks in October, Hazeltree Says
US stocks | Outstanding stocks soar again! Software giant Applovin surged 70% in the two days after the performance, skyrocketed 6 times in the year; it returned to the "trillion-dollar club"! Tesla skyrocketed 30% in a week.
The medical technology stocks are performing well! The largest US online platform for doctors, Doximity, surged by 30%, while the medical technology unicorn Tempus AI hit a new high in stock price; The network security giants are also celebrating! Security giant Axon Enterprise and fortinet jointly reached a new high.
Form 144 | Vertex Pharmaceuticals(VRTX.US) Officer Proposes to Sell 7.83 Million in Common Stocks
SEC FILLINGS DISCLOSED/ Nov 8, $Vertex Pharmaceuticals(VRTX.US)$ Officer Kewalramani Reshma intends to sell 15,198 shares of its common stock on Nov 8, with a total market value of approximately $7.83
Vertex Pharmaceuticals Faces Integration Challenges in Alpine Acquisition
Argus Raises Price Target on Vertex Pharmaceuticals to $550 From $530
Vertex Pharmaceuticals Price Target Raised to $408.00/Share From $361.00 by Canaccord Genuity
J.P. Morgan Maintains Vertex Pharmaceuticals(VRTX.US) With Buy Rating, Announces Target Price $503
CCORF Maintains Vertex Pharmaceuticals(VRTX.US) With Sell Rating, Raises Target Price to $408
A Quick Look at Today's Ratings for Vertex Pharmaceuticals(VRTX.US), With a Forecast Between $486 to $600
Vertex Pharmaceuticals Third Quarter 2024 Earnings: Beats Expectations
Vertex Pharmaceuticals: Strong Financial Performance and Innovative Drug Pipeline Underpin Buy Rating
Cautious Outlook: Evaluating Vertex Pharmaceuticals' Growth Potential Amidst Strong Performance and Speculative Risks
Vertex Pharmaceuticals Is Maintained at Sector Perform by Scotiabank
Vertex Pharmaceuticals | 10-Q: Q3 2024 Earnings Report
Sector Update: Health Care Stocks Rise Tuesday Afternoon